Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer

This is an open-label, multi-center, phase Ⅱ study. This study will evaluate the efficacy and safety of pembrolizumab in combination with disitamab vedotin in subject with HER2-expressing metastatic Colorectal Cancer (mCRC).